http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
박정민 ( Jung Min Park ),정노을 ( Noh Ul Jung ),조명란 ( Myeong Ran Jo ),강경희 ( Kyung Hee Kang ),이상보 ( Sang Bo Lee ),이상학 ( Sang Hak Lee ),홍지형 ( Ji Hyung Hong ),이석조 ( Suk Jo Lee ) 한국환경분석학회 2012 환경분석과 독성보건 Vol.15 No.2
In this study, mercury emissions from waste incineration(municipal, hazardous, medical, sludge) in Korea, were measured. Hg contained in waste vaporizes during waste incineration and is emitted through the stack. Waste incinerators(municipal, hazardous, medical, sewage sludge) are recognized as a major source of Hg emission into the atmosphere. However, waste composition varies widely depending on economic condition, technologies in use, management practices, handling and treatment of such wastes. On an average, Hg emission concentrations from municipal waste incineration ranged from 13.50 to 36.50 μg/Sm3 and 1.96 to 4.71 μg/Sm3, at inlet and outlet of APCDs, respectively. This corresponds to removal efficiency of 84.4%. Small-capacity incinerators showed higher Hg emissions, in general. Hg emission concentrations from hazardous waste incineration ranged from 67.33 to 563.16 μg/Sm3 and 120.97 to 129.68 μg/Sm3, at inlet and outlet of APCDs, respectively. The municipal wastes contain relatively less Hg, compared to hazardous wastes, leading to lower Hg concentration in flue gas emission. Average Hg emission concentrations from medical waste incineration were 475.95 μg/Sm3 and in the range of 123.87 to 51.48 μg/Sm3, at inlet and outlet of APCDs, respectively. While, average Hg emission concentrations from sewage sludge incineration were 251.23 μg/Sm3 and 16.66 μg/Sm3, at inlet and outlet of APCDs, respectively. Hg emission factors estimation for waste incineration was based on the sampling concentration of Hg, flue gas exhaust rate and waste burned. Waste types varied, depending on different type of incinerators: municipal, hazardous, medical waste. Hg sources are to be continued to be measured in the future to have a clear scenario of Hg emission from the country and to apply for effective control measures.
CJ-50002(비브리오백신)의 랫드 및 비글개에서의 단회투여 독성시험
이성학(Sung Hak Lee),임동문(Dong Moon Lim),김달현(Dal Hyun Kim),정상보(Sang Bo Jung),박완제(Wan Je Park),이영수(Young Soo Lee) 한국독성학회 1999 Toxicological Research Vol.15 No.2
The single dose toxicity test of CJ-50002, an oral Vibrio vaccine against Vibrio vulnificus injection, was performed in Sprague Dawley (SD) rats and beagle dogs. CJ-50002 was orally administered up to 500 mg/kg in SD rats and 167 mg/kg in beagle dogs. In these experiments, there were no death and clinical changes which were related to CJ-50002. In addition, there were no significant changes between control group and treated groups in body weights and autopsy findings. In conclusion, oral LD50 of CJ-50002 is over 500 mg/kg in SD rats and over 167 mg/kg in beagle dogs.
경구투여한 V. vulnificus 백신의 면역원성 및 감염방어효능
이나경(Na Gyong Lee),정상보(Sang Bo Jung),안보영(Bo Young Ahn),김영지(Young Gi Kim),이윤하(Youn Ha Lee),전영중(Young Joong Jeon),박완제(Wan Je Park) 한국응용약물학회 1998 Biomolecules & Therapeutics(구 응용약물학회지) Vol.6 No.2
Vibrion vulnificus is an estuarine gram0negative human pathogen that affects people with chronic hepatitis, alcoholic cirrhosis, diabetes mellitus or other underlying diseases, V. vulnificus infection is mediated primarily by consumption of raw fish or by exposure of pre-existing wounds to seawater, causing permanent tissue damages or fatal septic shock. We have been developing a vaccine against V. vulnificus composed of whole cell lysate of a V. vulnificus O-antigen serotype 4 strain. Oral administration of the V. vulnificus vaccine elicited a high serum antibody response in rabbits. The induced antibodies were reactive not only to the homologous strain but also to heterologous O-antigen serotype strains, indicating cross-reactivities among serotypes. Western blot analysis revealed that the antibodies are mainly specific for outer membrane proteins (OMPs) and reacted equally well with OPMs purified from 9 O-antigen serotypes The rabbit antisera showed opsonophagocytic killing activity against heterologous strains as well as the homologous strain. Passively transferred rabbit antisera into mice were protective against a lethal V. vulnificus infection. These data demonstrate that oral administration of the V. vulnificus infections, suggesting that this vaccine preparation could be used to develop an oral vaccine against V. vulnificus. Keywords □ V. vulnificus. oral vaccine, immunogenicity, protective efficacy
녹동균 세포외막 단백질 백신 CFC-1-101의 안정성 및 면역원성 검토 : 임상 제 Ⅰ/Ⅱa상 시험
장인진,김익상,유경상,임동석,김형기,신상구,장우현,박완제,이나경,정상보,안동호,조양제,안보영,이윤하,김영지,남성우,김현수 대한감염학회 1998 감염 Vol.30 No.3
목적 : 제일제당에서는 녹농균의 세포외막 단밸질을 유효성분으로 하는 백신인 CFC-101을 개발하였으며, 동물시험에서 이 백신의 안전성과 유효성을 입증하였다. 본 연구에서는 이 녹농균 백신의 인체에 대한 안전성과 면역원성을 평가하는 동시에 인체 접종시의 최적 투여 용량을 결정하기 위하여 제 I/Ⅱa상 임상시험을 수행하였다. 방법 : 건강한 성인 남자를 피험자로 선별하여 각 용량군에 백신투여자 6명, 위약투여자 2명을 배정하였다. 백신 투여군은 0.25mg, 0.5mg 또는 1.0mg 용량의 녹농균 백신을 7일 간격으로 3회에 걸쳐 근육주사 하였으며, 위약 투여군에게는 세포외막 단백질을 제외한 동일한 성분을 투여하였다. 백신접종 후 국소적 또는 전신적인 반응의 발생여부를 관찰하고, 혈액시료를 체취하여 백신의 역가와 유효성을 검정하였다. 결과 : 녹농균 백신 CFC-101은 모든 접종자에서 양호한 내약성을 보였다. 또한 0.5mg 과 1.0mg 백신 투여군에서는 100%의 항체양전율을 나타내었다. 생성된 항체는 녹농균 세포외막단백질에 특이성을 보였고, 녹농균 감염에 대해 방어효능이 있었다. 결론 : 이와같은 결과로부터 이 녹농균 백신은 인체에 안전하게 투여할 수 있으며, 높은 항체 생성능으로 감염방어 효능을 보이고 0.5mg과 1.0mg이 최적용량인 것으로 판단되었다. Background : We developed a Pseudomonas aeruginosa outer membrane protein(OMP) vaccine CFC-101, and the prophylactic efficacy of which has been demonstrated in animal models. In order to evaluate the safety and immunogenicity of the P. aeruginosa vaccine, we carried out a phase I/Ⅱa clinical trial in healthy male volunteers. Methods : Groups of eight volunteers, including two placebo subjects, were vaccinated intramuscularly with three doses of 0.25, 0.5 or 1.0 mg of the vaccine at one week intervals. Sings of systemic and local reactions observed after vaccination were recorded for each vaccinee for 5 days. Physical examinations were performed on days 0, 1, 7, 8, 14, 15, 21, and 42, and clinical laboratory tests were done on days 0, 3, and 21. Blood samples for assay of serum antibody levels were obtained up to 42 days after the first vaccination. Results : The vaccine was generally well tolerated by all vaccinees, showing no significant side effects. In the three dosage groups, all vaccinees, except one receiving the 0.25 mg dose, showed significant elevation in serum IgG antibody titers against the vaccine proteins, indicating 100% seroconversion in 0.5 and 1.0 mg groups. The human antibodies induced by the vaccine were specific for P. aeruginosa OMPs, as confirmed by western blot analysis and immunoprecipitation assays. The capacity of the human antisera to enhance opsonophagocytic killing activity by polymorphonuclear leukocytes and to confer protection against P. aeruginosa infections indicates that the antibodies elicited by the vaccine have protective efficacy. Conclusion : We conclude that the P. aeruginosa OMP vaccine is safe and effective for human use and its optimal dose to be 0.5 or 1.0 mg.